Search

• Japan’s Ministry of Health, Labour and Welfare approves Shingrix for the prevention of shingles in at-risk adults aged 18 and over

  Media

  Approval expands the number of people who can be protected against shingles.

  https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-shingrix-for-the-prevention-of-shingles-in-at-risk-adults-aged-18-and-over/

  First published: 26 June 2023

• Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award

  Media

  Organisations from South Africa, Zambia, Kenya and Uganda and Save the Children for innovations proven to help reduce deaths in under-fives

  https://www.gsk.com/en-gb/media/press-releases/four-initiatives-from-across-africa-win-share-of-global-us-1-million-healthcare-innovation-award/

  First published: 29 January 2015

• Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children

  Media

  Healthcare Innovation Award is a major initiative within five-year partnership to help save one million children’s lives

  https://www.gsk.com/en-gb/media/press-releases/four-inspiring-innovations-which-help-reduce-child-deaths-in-developing-countries-share-1-million-prize-from-gsk-and-save-the-children/

  First published: 23 February 2016

• ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV

  Media

  Juluca maintains viral suppression with two drugs in the smallest single pill regimen

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/

  First published: 21 May 2018

• New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

  Media

  GSK today announced new 48-week data from the MOMENTUM phase III trial...

  https://www.gsk.com/en-gb/media/press-releases/new-data-at-ash-underscore-the-potential-for-durable-clinically-important-responses-with-momelotinib-for-myelofibrosis-patients/

  First published: 11 December 2022

• Regulatory update: GSK and Theravance announce intention to file Relvar® Ellipta® for COPD in Japan

  Media

  GSK and THRX announced intention to file sJNDA for Relvar® Ellipta® for the treatment of COPD with the Japanese authority during the Q12016.

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-theravance-announce-intention-to-file-relvar-ellipta-for-copd-in-japan/

  First published: 24 September 2015

• New England Journal of Medicine and ERS publish positive results from GSK phase III studies of mepolizumab in patients with severe eosinophilic asthma

  Media

  NEJM presented at ERS data from Phase III asthma studies of mepolizumab, an investigational IL-5 antagonist monoclonal antibody.

  https://www.gsk.com/en-gb/media/press-releases/new-england-journal-of-medicine-and-ers-publish-positive-results-from-gsk-phase-iii-studies-of-mepolizumab-in-patients-with-severe-eosinophilic-asthma/

  First published: 08 September 2014

• GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease

  Media

  Study did not meet the primary endpoint measure.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-top-line-results-from-pivotal-phase-iii-study-of-darapladib-in-chronic-coronary-heart-disease/

  First published: 12 November 2013

• Four innovations to tackle under-five deaths win US$1 million Healthcare Innovation Award from GSK and Save the Children

  Media

  Organisations in Pakistan, Colombia, India and Nigeria recognised for innovations helping the hardest-to-reach children HIA (award).

  https://www.gsk.com/en-gb/media/press-releases/four-innovations-to-tackle-under-five-deaths-win-us-1-million-healthcare-innovation-award-from-gsk-and-save-the-children/

  First published: 05 June 2017

• GSK announces regulatory submissions for subcutaneous formulation of Benlysta® (belimumab) for patients with systemic lupus disease

  Media

  It has filed regulatory submissions in the US and Europe for Benlysta® (belimumab) for approval.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submissions-for-subcutaneous-formulation-of-benlysta-belimumab-for-patients-with-systemic-lupus-disease/

  First published: 23 September 2016